HF/Transplantation News

Adults with subclinical hypothyroidism may have a lower risk for major adverse cardiovascular events if they receive levothyroxine therapy compared with no treatment, according to a study published in Thyroid.

Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.

Abbott announced the FDA approved elimination of aspirin as part of routine management from the label of its fully magnetically levitated left ventricular assist device.

A novel prognostic model identified risk factors including smoking, obesity, HbA1c and albuminuria as significant predictors of incident heart failure risk among Native American adults, researchers reported.

Twelve circulating proteins associated with obesity and heart failure may inform treatment for adults with both conditions, according to a study published in Obesity.

Benzodiazepines were associated with increased risk for CHD, HF and CV mortality among patients with insomnia, according to a study published in the European Journal of Preventive Cardiology.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

Text messages delivered to patients’ smartwatches show promise to improve physical activity for those undergoing cardiac rehabilitation, but sustained behavioral change over time may remain a challenge, researchers reported.

Adults with type 2 diabetes who are referred to a clinical pharmacist are more likely to meet their HbA1c goal and receive appropriate medication management of comorbidities than people receiving usual care, according to a presenter.

HU6, a controlled metabolic accelerator, met the primary endpoint of weight reduction in patients with obesity-related heart failure with preserved ejection fraction, according to top-line results of the phase 2a HuMAIN trial.